Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IV gammaglobulin for severe COVID-19 (double-blind RCT)
2020-001890-56Phase 4Active
- Sponsor
- Universidad Católica San Antonio de Murcia
- Start
- Jul 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing IV immunoglobulin with Placebo (2 arms). Primary endpoint: Mortality. Started Jul 2020; status: active.
02
Drugs
immune globulin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-001890-56.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001890-56.